SK Biopharmaceuticals CEO Lee Dong-hoon speaks during a press conference held in western Seoul on Tuesday. [SK BIOPHARMACEUTICALS] SK Biopharmaceuticals aims to turn its epilepsy drug Cenobamate into a blockbuster with annual sales of $1 billion, the company said Tuesday. The Seongnam, Gyeonggi-based biopharmaceutical company expects to swing back into profit next year with global sales of Cenobamate, which is being marketed under the brand Xcopri in the United States, and hopes to achieve an enterprise value of $15 billion by 2026.

https://n.news.naver.com/mnews/article/640/0000040910?sid=101

#naver